# Scribe Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scribe-therapeutics

- Industry: Biotechnology
- Headquarters: Alameda, US
- Website: www.scribetx.com
- Total disclosed funding: $120M
- Latest round: Series B (Mar 17, 2021)
- Investors on record: 9

## About

Scribe Therapeutics, Inc. is a US-based biotech company specializing in innovative CRISPR-based therapeutics aimed at addressing major genetic health issues, particularly in cardiometabolic diseases.Scribe Therapeutics, Inc. is dedicated to developing advanced CRISPR technologies for therapeutic applications. Founded in 2018 by Benjamin Oakes and Brett Staahl, the company is headquartered in Alameda, California, US. It has secured a total of USD 100.00 mn through its Series B funding round on March 17, 2021, led by Avoro Capital Advisors and supported by investors including Andreessen Horowitz and T. Rowe Price. The total amount raised by the company stands at USD 100.00 mn, with a current valuation of USD 299.77 mn.Scribe Therapeutics focuses on developing innovative CRISPR-based therapeutics to tackle significant genetic health challenges, especially cardiometabolic diseases, which are a leading global cause of death. Their offerings include CRISPR technologies that aim to provide safe and effective solutions for a variety of diseases. The company emphasizes molecular engineering to ensure the safety and specificity of its CRISPR systems, addressing both inherited and chronic conditions. Scribe Therapeutics collaborates with leading pharmaceutical companies, aiming to make its therapies widely accessible, particularly in North America and Europe.Scribe Therapeutics generates revenue primarily through strategic partnerships with pharmaceutical companies and collaborative agreements for the research and development of CRISPR-based therapies. The company engages in B2B transactions, working with larger entities on the development and commercialization of therapeutic products. Revenue is derived from milestone payments and royalties contingent on the successful advancement of its therapies through clinical trials and regulatory approvals, though specific pricing plans for flagship products have not been publicly disclosed.Following its recent Series B funding of USD 100.00 mn in March 2021, Scribe Therapeutics plans to utilize these resources to further develop its gene editing and delivery technologies. The company is focused on advancing a pipeline of therapeutics for neurodegeneration and other diseases. Scribe Therapeutics aims to expand its market reach beyond current territories, with specific plans to enter additional markets in North America and Europe by 2023, thereby broadening its impact on global health challenges.

## Funding rounds

- Series B, Mar 17, 2021, $100M — Menlo Ventures, OrbiMed Advisors, T Rowe Price, Wellington Management, Andreessen Horowitz, RA Capital Management, Perceptive Advisors, Avoro Capital Advisors
- Series A, Oct 6, 2018, $20M — Andreessen Horowitz, Biogen, Inc.

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A, Series B
- Biogen, Inc. — Series A
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Avoro Capital Advisors — Series B